# EDGAR Filing Document

**Accession Number:** 0001762176
**File Stem:** 0001470831-26-000086
**Filing Date:** 2026-2
**Character Count:** 8764
**Document Hash:** c49921c9adf38dc05fbc6882ed56048d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001470831-26-000086.hdr.sgml**: 20260203

**ACCESSION NUMBER**: 0001470831-26-000086

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260201

**FILED AS OF DATE**: 20260203

**DATE AS OF CHANGE**: 20260203

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Anderson Karen M.
- **CENTRAL INDEX KEY:** 0001762176

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40445
- **FILM NUMBER:** 26595263

**MAIL ADDRESS:**
- **STREET 1:** C/O CENTESSA PHARMACEUTICALS PLC
- **STREET 2:** 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM
- **CITY:** CHESHIRE
- **STATE:** X0
- **ZIP:** WA14 2DT
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Centessa Pharmaceuticals plc
- **CENTRAL INDEX KEY:** 0001847903
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 3RD FLOOR
- **STREET 2:** 1 ASHLEY ROAD
- **CITY:** ALTRINCHAM, CHESHIRE
- **STATE:** X0
- **ZIP:** WA14 2DT
- **BUSINESS PHONE:** 44 7391 789784

**MAIL ADDRESS:**
- **STREET 1:** 3RD FLOOR
- **STREET 2:** 1 ASHLEY ROAD
- **CITY:** ALTRINCHAM, CHESHIRE
- **STATE:** X0
- **ZIP:** WA14 2DT

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Centessa Pharmaceuticals Ltd
- **DATE OF NAME CHANGE:** 20210224

## Ex-24

```

SUBSTITUTE POWER OF ATTORNEY

Under the terms of powers of attorney (each, a "Power of Attorney") previously
filed with the U.S. Securities and Exchange Commission, the undersigned was
appointed an attorney-in-fact for the below listed individuals to, among other
things, execute for and on behalf of the following individuals any Form 3, Form
4, or Form 5; Schedule 13D or Schedule 13G; or Form 144, or any amendment(s)
thereto, in accordance with Section 13 or Section 16 of the Securities Exchange
Act of 1934 and the rules and regulations promulgated thereunder, or pursuant to
Rule 144 under the Securities Act of 1933 and the rules and regulations
promulgated thereunder:

Saurabh Saha
Iqbal J. Hussain
Tia L. Bush
Karen M. Anderson
John J. Crowley
Stephen Kanes
Raphael Deferiere
Mario Alberto Accardi
Francesco De Rubertis
Arjun Goyal
Brett I.W. Zbar
Mary Lynne Hedley
Samarth Kulkarni
Carol Stuckley
Mathias Hukkelhoven

In accordance with the authority granted under each Power of Attorney, including
the full power of substitution, the undersigned hereby appoints Raphael
Deferiere as substitute attorney-in-fact, on behalf of the individuals listed
above, with the power to exercise and execute all of the powers granted or
conferred in the original Power of Attorney. For the avoidance of doubt, the
foregoing appointment shall not serve as a revocation of the powers granted to
the undersigned himself in each Power of Attorney.

This substitute Power of Attorney shall remain in full force and effect with
respect to each Power of Attorney until such underlying Power of Attorney is
revoked or terminated, unless earlier revoked by the undersigned in a signed
writing.

Date: 08/11/2025

By: /s/ Gregory Weinhoff
Name: Gregory Weinhoff
Title: Attorney-in-Fact

```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Anderson Karen M.<br><sub>(Last) (First) (Middle)</sub><br>C/O CENTESSA PHARMACEUTICALS PLC<br>3RD FL., 1 ASHLEY RD, ALTRINCHAM<br><sub>(Street)</sub><br>CHESHIRE, X0 WA14 2DT<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-02-01 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chief People Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Centessa Pharmaceuticals plc [ CNTA ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Ordinary Shares<sup>(1)</sup> | 2026-02-01 |  | F |  | 10606<sup>(2)</sup> | D | $24.57 | 43716 | D |  |
| Ordinary Shares<sup>(1)</sup> | 2026-02-02 |  | A |  | 29000<sup>(3)</sup> | A | $0 | 72716 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Share Option (right to buy) | $25.19 | 2026-02-02 |  | A |  | 117000 |  | <sup>(4)</sup> | 2036-02-02 | Ordinary Shares<sup>(1)</sup> | 117000 | $0 | 117000 | D |  |

---

### Footnotes:

(1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

(2) Represents the number of shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of restricted share units.

(3) The shares reported in this transaction represent Restricted Share Units ("RSUs") issued under the Centessa Pharmaceuticals plc Amended and Restated 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one Ordinary Share of the Issuer. The RSUs shall vest and be settled in four equal annual installments with the first such annual vesting being on February 2, 2027.

(4) 1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 2, 2026.

**Remarks:**
Exhibit 24.2 - Substitute Power of Attorney

**Signature:** /s/ Raphael Deferiere, attorney-in-fact  
**Date:** 2026-02-03

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**